APLS Apellis Stock Forecast 2023
Latest Appelis APLS Stock Price
Article Coverage: About the Company, Latest APLS News, Analyst Forecasts, Aggregated Forecasts, APLS Latest Production Update, Reasons to Buy or Sell APLS Stock, FAQs and Other detailed analysis.
Apellis Pharmaceuticals, Inc. (APLS) is a clinical-stage biopharmaceutical company that focuses on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system.
Apellis Pharmaceuticals, Inc. (APLS) is traded on the Nasdaq stock exchange under the ticker symbol “APLS.”
Apellis Stock Forecast 2023: Latest News
- Apellis Pharma will present at upcoming investor conferences, including the Cowen Healthcare Conference on August 8, 2023 and the Jefferies Healthcare Conference on August 9, 2023.
- Apellis Pharma announced positive top-line results from phase 3 trial of pegcetacoplan for geographic atrophy on July 29, 2023. The trial met its primary endpoint of slowing the progression of geographic atrophy.
Apellis Stock Price Target: Analysts
| APLS Price Forecast (Next 12 months) | $65.4 |
| Citigroup | $80 |
| HC Wainwright & Co. | $82 |
| Wedbush | $40 |
| Wells Fargo | $53 |
| JP Morgan | $72 |
Apellis Stock Forecast Today
| Overall Outlook | Neutral |
| 1. Market's Wisdom | Neutral |
| 1a. Market Data | Neutral |
| 1b. Technical Recommendation | Neutral |
| 2. Crowd's Wisdom | Neutral |
| 2a. Social Media Buzz | Steady |
| 2b. Social Media Sentiment | Steady |
Apellis Stock Forecast 2023: Is APLS a good stock to buy?
Apellis Pharmaceuticals, Inc. (APLS) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutic compounds to treat disease through the inhibition of the complement system. The complement system is an integral component of the immune system, and it plays a role in a variety of diseases, including autoimmune diseases, eye diseases, and cancer.
APLS has a number of promising drug candidates in its pipeline, including APL-2, which is being developed for the treatment of pemphigus vulgaris, and APL-3, which is being developed for the treatment of geographic atrophy. The company also has a number of other drug candidates in early-stage development.
APLS is still a relatively young company, and it has not yet generated significant revenue. However, the company’s financial performance has been improving, and it is on track to become profitable in the near future.
| (USD) | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
| Revenue | 44.85M | 22.66M | 22.06M | 16.32M |
| Net income | -177.78M | -165.99M | -191.27M | -155.98M |
| Diluted EPS | -1.56 | -1.5 | – | – |
| Net profit margin | -396.42% | -732.43% | -867.20% | -955.62% |
| Operating income | -175.08M | -164.05M | -152.94M | -148.62M |
| Net change in cash | 213.28M | -32.37M | -20.31M | -29.26M |
| Cost of revenue | 117.84M | -284.89M | 96.59M | 101.74M |
In the last 4 quarters, there has been a significant increase in the revenue of Apellis Pharmaceuticals but the income margin has deteriorated. Overall the stock has failed to deliver the earnings that could attract more investors.
Added to it Apellis Pharmaceuticals is not the only company developing drugs that target the complement system. There are a number of other companies in this space, and some of them have larger pipelines or more advanced drug candidates.
Overall, APLS is a risky investment. Investors should carefully consider the risks and rewards before making a decision.
APLS Prediction 2023: Reasons Not to Buy APLS Stock
The company’s drug candidates are still in the early stages of development. There is always the risk that they may not be successful, or that they may be approved with limitations that make them less profitable.
The company is still relatively young and has not yet generated significant revenue. This means that the company is more likely to be volatile and that there is more risk of losing money if you invest in it.
The regulatory environment is constantly changing. This could delay or even prevent the approval of APLS’s drug candidates, which would be a major setback for the company.
The market for APLS’s products is still in its early stages of development. It is not yet clear how large this market will be, or how much revenue APLS will be able to generate from its products. This means that there is a lot of uncertainty about the company’s future prospects.
APLS Stock Price Prediction: How High Will APLS Go in 2023?
It is difficult to say how high APLS stock will go in 2023. The company has a number of promising drug candidates in its pipeline, but they are still in the early stages of development. There is always the risk that they may not be successful, or that they may be approved with limitations that make them less profitable.
However, if APLS’s drug candidates are successful, the company could see significant growth in revenue and profit. This could lead to a significant increase in the stock price.
According to Top analysts, the average price target for APLS stock is $84.43. This suggests the stock could reach $84.43 per share in 2023. However, it is important to note that this is just an average price target, and the actual price could be higher or lower.
Apellis Stock Forecast: Will APLS Break above $100 in 2023?
It is possible that APLS stock could break above $100 in 2023. However, there are a number of factors that could influence the stock price, and it is impossible to say for sure whether or not it will reach this level.
If APLS’s drug candidates are successful and the company is able to raise additional capital, the stock price could potentially reach $100 or higher. However, if the clinical trials are unsuccessful or the regulatory environment becomes more unfavorable, the stock price could decline.
Ultimately, the decision of whether or not to buy APLS stock in 2023 is a personal one. Investors should carefully consider the risks and rewards before making a decision.
APLS Stock Forecast: Frequently Asked Questions (FAQ)
Should I buy APLS Stock Now?
Whether or not you should buy APLS stock now is a personal decision. There are a number of factors to consider, including the company’s pipeline of drug candidates, its financial performance, its management team, the competitive landscape, and the regulatory environment.
Here are some of the pros and cons of buying APLS stock now:
- The company has a number of promising drug candidates in its pipeline.
- The company’s financial performance has been improving.
- The company’s drug candidates are still in the early stages of development, so there is always the risk that they may not be successful.
- The company is still relatively young and has not yet generated significant revenue.
Will APLS Stock go up?
It is impossible to say for sure whether or not APLS stock will go up. The stock price is influenced by a number of factors, including the company’s pipeline of drug candidates, its financial performance, its management team, the competitive landscape, and the regulatory environment.
How much will APLS Stock Be Worth in 10 Years?
It is difficult to say how much APLS stock will be worth in 10 years. The stock price is influenced by a number of factors, including the company’s pipeline of drug candidates, its financial performance, its management team, the competitive landscape, and the regulatory environment.
If we assume that APLS stock continues to grow at a similar rate over the next 10 years, it is possible that the stock could be worth $150 or more per share in 2033. However, it is also possible that the stock could be worth significantly less.
What is the best time to invest in APLS stock?
There is no one-size-fits-all answer to this question, as the best time to invest in APLS stock will depend on your individual circumstances and investment goals.
How High Will APLS go?
It is impossible to say for sure how high APLS stock will go. The stock price is influenced by a number of factors, including the company’s pipeline of drug candidates, its financial performance, its management team, the competitive landscape, and the regulatory environment.
If these factors come to pass, it is possible that APLS stock could go up significantly in the future. However, it is important to remember that there are also risks associated with investing in APLS stock.
Check out other Stock Forecasts
Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.